BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37068265)

  • 1. High-Contrast PET Imaging with [
    Turkman N; Xu S; Huang CH; Eyermann C; Salino J; Khan P
    J Med Chem; 2023 Apr; 66(8):5611-5621. PubMed ID: 37068265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, biochemical evaluation, radiolabeling and in vivo imaging with high affinity class-IIa histone deacetylase inhibitor for molecular imaging and targeted therapy.
    Turkman N; Liu D; Pirola I
    Eur J Med Chem; 2022 Jan; 228():114011. PubMed ID: 34875522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Histone Deacetylase Class IIa Selective Substrate Radiotracers for PET Imaging of Epigenetic Regulation in the Brain.
    Bonomi R; Mukhopadhyay U; Shavrin A; Yeh HH; Majhi A; Dewage SW; Najjar A; Lu X; Cisneros GA; Tong WP; Alauddin MM; Liu RS; Mangner TJ; Turkman N; Gelovani JG
    PLoS One; 2015; 10(8):e0133512. PubMed ID: 26244761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [
    Laws MT; Bonomi RE; Kamal S; Gelovani DJ; Llaniguez J; Potukutchi S; Lu X; Mangner T; Gelovani JG
    Sci Rep; 2019 Mar; 9(1):3595. PubMed ID: 30837601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Class IIa Histone Deacetylases Expression and In Vivo Epigenetic Imaging in a Transgenic Mouse Model of Alzheimer's Disease.
    Chen YA; Lu CH; Ke CC; Chiu SJ; Chang CW; Yang BH; Gelovani JG; Liu RS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with ¹⁸F-FAHA.
    Yeh HH; Tian M; Hinz R; Young D; Shavrin A; Mukhapadhyay U; Flores LG; Balatoni J; Soghomonyan S; Jeong HJ; Pal A; Uthamanthil R; Jackson JN; Nishii R; Mizuma H; Onoe H; Kagawa S; Higashi T; Fukumitsu N; Alauddin M; Tong W; Herholz K; Gelovani JG
    Neuroimage; 2013 Jan; 64():630-9. PubMed ID: 22995777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and Evaluation of
    Li MH; Chang HC; Feng CF; Yu HW; Shiue CY
    Curr Med Imaging; 2020; 16(8):978-990. PubMed ID: 33081659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.
    Zeglis BM; Pillarsetty N; Divilov V; Blasberg RA; Lewis JS
    Nucl Med Biol; 2011 Jul; 38(5):683-96. PubMed ID: 21718944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the Development of PET Ligands Targeting Histone Deacetylases for the Assessment of Neurodegenerative Diseases.
    Tago T; Toyohara J
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain.
    Reid AE; Hooker J; Shumay E; Logan J; Shea C; Kim SW; Collins S; Xu Y; Volkow N; Fowler JS
    Nucl Med Biol; 2009 Apr; 36(3):247-58. PubMed ID: 19324270
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Fukumitsu N; Yeh SH; Flores Ii LG; Mukhopadhyay U; Young D; Ogawa K; Jeong HJ; Tong W; Gelovani JG
    Contrast Media Mol Imaging; 2018; 2018():3612027. PubMed ID: 29755299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.
    Luckhurst CA; Aziz O; Beaumont V; Bürli RW; Breccia P; Maillard MC; Haughan AF; Lamers M; Leonard P; Matthews KL; Raphy G; Stott AJ; Munoz-Sanjuan I; Thomas B; Wall M; Wishart G; Yates D; Dominguez C
    Bioorg Med Chem Lett; 2019 Jan; 29(1):83-88. PubMed ID: 30463802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel late-stage radiosynthesis of 5-[18F]-trifluoromethyl-1,2,4-oxadiazole (TFMO) containing molecules for PET imaging.
    Turkman N; Liu D; Pirola I
    Sci Rep; 2021 May; 11(1):10668. PubMed ID: 34021207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FNDP for PET Imaging of Soluble Epoxide Hydrolase.
    Horti AG; Wang Y; Minn I; Lan X; Wang J; Koehler RC; Alkayed NJ; Dannals RF; Pomper MG
    J Nucl Med; 2016 Nov; 57(11):1817-1822. PubMed ID: 27417650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial and temporal dynamics of HDACs class IIa following mild traumatic brain injury in adult rats.
    Kamal SR; Potukutchi S; Gelovani DJ; Bonomi RE; Kallakuri S; Cavanaugh JM; Mangner T; Conti A; Liu RS; Pasqualini R; Arap W; Sidman RL; Perrine SA; Gelovani JG
    Mol Psychiatry; 2022 Mar; 27(3):1683-1693. PubMed ID: 35027678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA).
    Hendricks JA; Keliher EJ; Marinelli B; Reiner T; Weissleder R; Mazitschek R
    J Med Chem; 2011 Aug; 54(15):5576-82. PubMed ID: 21721525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET imaging demonstrates histone deacetylase target engagement and clarifies brain penetrance of known and novel small molecule inhibitors in rat.
    Schroeder FA; Wang C; Van de Bittner GC; Neelamegam R; Takakura WR; Karunakaran A; Wey HY; Reis SA; Gale J; Zhang YL; Holson EB; Haggarty SJ; Hooker JM
    ACS Chem Neurosci; 2014 Oct; 5(10):1055-62. PubMed ID: 25188794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain.
    Seo YJ; Muench L; Reid A; Chen J; Kang Y; Hooker JM; Volkow ND; Fowler JS; Kim SW
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6700-5. PubMed ID: 24210501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical validation of a novel brain-penetrant PET ligand for visualization of histone deacetylase 6: a potential imaging target for neurodegenerative diseases.
    Tago T; Sakata M; Kanazawa M; Yamamoto S; Ishii K; Toyohara J
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2193-2203. PubMed ID: 38441662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Class IIa HDACs: Insights from Phenotypes and Inhibitors.
    Liu L; Dong L; Bourguet E; Fairlie DP
    Curr Med Chem; 2021; 28(42):8628-8672. PubMed ID: 34212828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.